Cargando…

Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy

Prostate cancer is the second most common cancer in men worldwide. Despite an abundance of prostate-specific antigens, immunotherapies have yet to become a standard of care, potentially limited by T-cell dysfunction. Up to 10% of human circulating T-cells, and a significant fraction in the urogenita...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarvis, Ellie-May, Collings, Shaun, Authier-Hall, Astrid, Dasyam, Nathaniel, Luey, Brendan, Nacey, John, Painter, Gavin F., Delahunt, Brett, Hermans, Ian F., Weinkove, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560687/
https://www.ncbi.nlm.nih.gov/pubmed/34737749
http://dx.doi.org/10.3389/fimmu.2021.748741
_version_ 1784592969470312448
author Jarvis, Ellie-May
Collings, Shaun
Authier-Hall, Astrid
Dasyam, Nathaniel
Luey, Brendan
Nacey, John
Painter, Gavin F.
Delahunt, Brett
Hermans, Ian F.
Weinkove, Robert
author_facet Jarvis, Ellie-May
Collings, Shaun
Authier-Hall, Astrid
Dasyam, Nathaniel
Luey, Brendan
Nacey, John
Painter, Gavin F.
Delahunt, Brett
Hermans, Ian F.
Weinkove, Robert
author_sort Jarvis, Ellie-May
collection PubMed
description Prostate cancer is the second most common cancer in men worldwide. Despite an abundance of prostate-specific antigens, immunotherapies have yet to become a standard of care, potentially limited by T-cell dysfunction. Up to 10% of human circulating T-cells, and a significant fraction in the urogenital tract, are mucosal-associated invariant T (MAIT) cells. MAIT cells express stereotyped T-cell receptors that recognize riboflavin metabolites derived from microbes presented by MR-1. We evaluated the number, phenotype and function of circulating MAIT cells, alongside two other innate-like T (ILT) -cell subsets, in men with prostate cancer and age- and sex-matched controls. MAIT cells in men with prostate cancer circulated at similar frequencies to controls, but their cytokine production and proliferation was impaired. In contrast, the function of two other ILT-cell populations (natural killer T-cells and Vγ9Vδ2 T-cells) was not impaired. In both patients and controls, MAIT cells expressed high levels of the immune checkpoint molecule PD-1 at rest, while upregulation of PD-1 in response to the MR-1 ligand 5-amino-6D-ribitylaminouracil (5-A-RU) was greater in patients. 5-A-RU also induced upregulation of PD-L1 and -L2 RNA in primary mononuclear cells. We confirmed that circulating MAIT cell number and function were preserved before and during anti-PD1 therapy with pembrolizumab in a cohort of patients with melanoma. In vitro, 5-A-RU enhanced mononuclear cell cytotoxicity against the PD-L1 positive prostate cancer cell line PC3 in an MR-1-dependent manner. Addition of pembrolizumab enhanced this cytotoxicity, and was associated with increased MAIT cell expression of CD107a and IFN-γ. We conclude that prostate cancer is associated with MAIT-cell dysfunction, and that this might be overcome through the application of potent MR-1 ligands with PD-1 blockade. These findings may have implications for the development of cancer immunotherapies that exploit MAIT cells.
format Online
Article
Text
id pubmed-8560687
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85606872021-11-03 Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy Jarvis, Ellie-May Collings, Shaun Authier-Hall, Astrid Dasyam, Nathaniel Luey, Brendan Nacey, John Painter, Gavin F. Delahunt, Brett Hermans, Ian F. Weinkove, Robert Front Immunol Immunology Prostate cancer is the second most common cancer in men worldwide. Despite an abundance of prostate-specific antigens, immunotherapies have yet to become a standard of care, potentially limited by T-cell dysfunction. Up to 10% of human circulating T-cells, and a significant fraction in the urogenital tract, are mucosal-associated invariant T (MAIT) cells. MAIT cells express stereotyped T-cell receptors that recognize riboflavin metabolites derived from microbes presented by MR-1. We evaluated the number, phenotype and function of circulating MAIT cells, alongside two other innate-like T (ILT) -cell subsets, in men with prostate cancer and age- and sex-matched controls. MAIT cells in men with prostate cancer circulated at similar frequencies to controls, but their cytokine production and proliferation was impaired. In contrast, the function of two other ILT-cell populations (natural killer T-cells and Vγ9Vδ2 T-cells) was not impaired. In both patients and controls, MAIT cells expressed high levels of the immune checkpoint molecule PD-1 at rest, while upregulation of PD-1 in response to the MR-1 ligand 5-amino-6D-ribitylaminouracil (5-A-RU) was greater in patients. 5-A-RU also induced upregulation of PD-L1 and -L2 RNA in primary mononuclear cells. We confirmed that circulating MAIT cell number and function were preserved before and during anti-PD1 therapy with pembrolizumab in a cohort of patients with melanoma. In vitro, 5-A-RU enhanced mononuclear cell cytotoxicity against the PD-L1 positive prostate cancer cell line PC3 in an MR-1-dependent manner. Addition of pembrolizumab enhanced this cytotoxicity, and was associated with increased MAIT cell expression of CD107a and IFN-γ. We conclude that prostate cancer is associated with MAIT-cell dysfunction, and that this might be overcome through the application of potent MR-1 ligands with PD-1 blockade. These findings may have implications for the development of cancer immunotherapies that exploit MAIT cells. Frontiers Media S.A. 2021-10-19 /pmc/articles/PMC8560687/ /pubmed/34737749 http://dx.doi.org/10.3389/fimmu.2021.748741 Text en Copyright © 2021 Jarvis, Collings, Authier-Hall, Dasyam, Luey, Nacey, Painter, Delahunt, Hermans and Weinkove https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jarvis, Ellie-May
Collings, Shaun
Authier-Hall, Astrid
Dasyam, Nathaniel
Luey, Brendan
Nacey, John
Painter, Gavin F.
Delahunt, Brett
Hermans, Ian F.
Weinkove, Robert
Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy
title Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy
title_full Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy
title_fullStr Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy
title_full_unstemmed Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy
title_short Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy
title_sort mucosal-associated invariant t (mait) cell dysfunction and pd-1 expression in prostate cancer: implications for immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560687/
https://www.ncbi.nlm.nih.gov/pubmed/34737749
http://dx.doi.org/10.3389/fimmu.2021.748741
work_keys_str_mv AT jarviselliemay mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT collingsshaun mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT authierhallastrid mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT dasyamnathaniel mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT lueybrendan mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT naceyjohn mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT paintergavinf mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT delahuntbrett mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT hermansianf mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy
AT weinkoverobert mucosalassociatedinvarianttmaitcelldysfunctionandpd1expressioninprostatecancerimplicationsforimmunotherapy